相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients
Eva Ellebaek et al.
CANCER EPIDEMIOLOGY (2021)
Efficacy of immune checkpoint inhibitors and age in cancer patients
Xuan-zhang Huang et al.
IMMUNOTHERAPY (2020)
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Brian Diskin et al.
NATURE IMMUNOLOGY (2020)
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+and CD4+T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
Souvik Dey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Patrick A. Ott et al.
CELL (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Ugur Sahin et al.
NATURE (2020)
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Xin Yan et al.
FRONTIERS IN ONCOLOGY (2020)
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
Nicolai Gronne Jorgensen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Anti-cancer immunotherapy: breakthroughs and future strategies
Mads Hald Andersen
SEMINARS IN IMMUNOPATHOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma
Lars Bastholt et al.
EUROPEAN JOURNAL OF CANCER (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The targeting of tumor-associated macrophages by vaccination
Mads Hald Andersen
CELL STRESS (2019)
The Balance Players of the Adaptive Immune System
Mads Hald Andersen
CANCER RESEARCH (2018)
A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
Tingting Wang et al.
NATURE COMMUNICATIONS (2018)
Warming Cold Melanoma with TLR9 Agonists
Alissa Poh
CANCER DISCOVERY (2018)
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
John E. Mullinax et al.
FRONTIERS IN ONCOLOGY (2018)
Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study - A Brief Research Report
Julie Westerlin Kjeldsen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
PD-L1-specific T cells
Shamaila Munir Ahmad et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen et al.
CLINICAL CANCER RESEARCH (2016)
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Jeffrey S. Weber et al.
ONCOLOGIST (2016)
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Shamaila Munir Ahmad et al.
ONCOIMMUNOLOGY (2016)
Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection
William S. DeWitt et al.
JOURNAL OF VIROLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen et al.
CLINICAL CANCER RESEARCH (2014)
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
S. M. Ahmad et al.
LEUKEMIA (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity
S. M. Ahmad et al.
BLOOD CANCER JOURNAL (2014)
HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
Shamaila Munir et al.
CANCER RESEARCH (2013)
Using synthetic templates to design an unbiased multiplex PCR assay
Christopher S. Carlson et al.
NATURE COMMUNICATIONS (2013)
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells
Shamaila Munir et al.
ONCOIMMUNOLOGY (2013)
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
Mads Hald Andersen
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Ultra-sensitive detection of rare T cell clones
Harlan Robins et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
Shamaila Munir et al.
PLOS ONE (2012)
Characterization and Comparison of Standard' and Young' Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution
M. Donia et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Rikke Baek Sorensen et al.
BLOOD (2011)
High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
Ozcan Met et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
Rikke Baek Sorensen et al.
CANCER RESEARCH (2011)
siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells
Willemijn Hobo et al.
BLOOD (2010)
Response definition criteria for ELISPOT assays revisited
Z. Moodie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
A SIMPLE FORWARD SELECTION PROCEDURE BASED ON FALSE DISCOVERY RATE CONTROL
Yoav Benjamini et al.
ANNALS OF APPLIED STATISTICS (2009)
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan S. Robins et al.
BLOOD (2009)
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Rikke Baek Sorensen et al.
PLOS ONE (2009)
HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals
Sandra A. Calarota et al.
JOURNAL OF IMMUNOLOGY (2008)
Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients
A Meier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes
B Godard et al.
HUMAN IMMUNOLOGY (2004)
分享论文
